Proactive Investors - Run By Investors For Investors

Sienna Cancer Diagnostics to launch its in-vitro test in Denmark and Sweden

New distribution agreement to accelerate the global roll out of Sienna’s hTERT IVD test.
Cancer header on a newspaper
Sienna's test help urologists detect bladder cancer

Sienna Cancer Diagnostics Ltd (ASX:SDX) has appointed Axlab A/S as the exclusive distribution partner for its in-vitro diagnostic (IVD) tests in Denmark and Sweden.

The Australia based Sienna’s hTERT test help urologists to detect bladder cancer earlier, and thereby improve patient welfare and lower overall costs in the healthcare system.

This new distribution agreement will broaden and accelerate the global roll out of Sienna’s hTERT IVD test.

Additionally, the agreement provides Axlab with the right to sell Sienna’s product to pathology laboratories.

Axlab is a Denmark based experienced supplier of instruments, reagents and consumables for histology and cytology.

Sienna plans to penetrate its products into the Nordic market using Axlab’s existing facilities and significant knowledge in cytology.

Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009.

The regulation of telomerase activity in human cells plays a significant role in the development of cancer.

Importantly, clinical pathology laboratories in the region may now purchase Sienna’s IVD product to detect the presence of hTERT, a component of telomerase.

View full SDX profile View Profile

Sienna Cancer Diagnostics Ltd Timeline

Related Articles

Collagen testing
August 17 2018
Since reporting its full-year results on July 10, the AIM-listed shares have rallied over 38% in the past month to 3.65p currently, taking year-to-date gains to a third
blood samples in test tubes
October 26 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use